BTIG Research Boosts Astrana Health (NASDAQ:ASTH) Price Target to $70.00

Astrana Health (NASDAQ:ASTHFree Report) had its target price raised by BTIG Research from $60.00 to $70.00 in a report issued on Thursday morning, Benzinga reports. The brokerage currently has a buy rating on the stock.

Several other analysts also recently issued reports on the company. Truist Financial lifted their target price on Astrana Health from $50.00 to $59.00 and gave the company a buy rating in a research note on Friday, August 9th. Stifel Nicolaus upped their target price on shares of Astrana Health from $48.00 to $60.00 and gave the stock a buy rating in a research report on Thursday, August 1st. Finally, Robert W. Baird lifted their price target on shares of Astrana Health from $54.00 to $67.00 and gave the company an outperform rating in a report on Thursday, August 15th. Five equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the stock has an average rating of Buy and an average target price of $61.20.

View Our Latest Research Report on ASTH

Astrana Health Price Performance

Shares of NASDAQ:ASTH opened at $59.89 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 1.84 and a current ratio of 1.84. The firm has a market cap of $3.36 billion, a price-to-earnings ratio of 45.37, a price-to-earnings-growth ratio of 2.15 and a beta of 1.21. The business has a 50-day simple moving average of $51.12 and a two-hundred day simple moving average of $44.57. Astrana Health has a fifty-two week low of $28.86 and a fifty-two week high of $61.51.

Astrana Health (NASDAQ:ASTHGet Free Report) last released its quarterly earnings data on Wednesday, August 7th. The company reported $0.40 earnings per share for the quarter, beating the consensus estimate of $0.39 by $0.01. The firm had revenue of $486.30 million during the quarter, compared to analysts’ expectations of $440.68 million. Astrana Health had a net margin of 4.30% and a return on equity of 10.71%. The firm’s quarterly revenue was up 39.7% on a year-over-year basis. During the same period in the previous year, the company earned $0.28 earnings per share. On average, analysts expect that Astrana Health will post 1.33 earnings per share for the current year.

Institutional Trading of Astrana Health

Several institutional investors and hedge funds have recently made changes to their positions in ASTH. Central Pacific Bank Trust Division purchased a new stake in shares of Astrana Health in the third quarter valued at approximately $160,000. Granite Bay Wealth Management LLC bought a new stake in Astrana Health during the 3rd quarter valued at $290,000. Handelsbanken Fonder AB purchased a new stake in shares of Astrana Health in the 3rd quarter worth $492,000. Finally, SG Americas Securities LLC bought a new position in shares of Astrana Health during the 3rd quarter worth $680,000. 52.77% of the stock is currently owned by institutional investors.

About Astrana Health

(Get Free Report)

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients.

Further Reading

Analyst Recommendations for Astrana Health (NASDAQ:ASTH)

Receive News & Ratings for Astrana Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrana Health and related companies with MarketBeat.com's FREE daily email newsletter.